We are delighted to announce the publication of our latest manuscript, "The Spatially Informed mFISHseq Assay Resolves Biomarker Discordance and Predicts Treatment Response in Breast Cancer," in a renowned journal Nature Communications. This milestone reflects years of dedication and collaboration, showcasing our innovative work in breast cancer diagnostics and personalized treatment strategies.
The study introduces our mFISHseq platform, a groundbreaking approach that combines RNA-FISH with RNA sequencing, guided by laser capture microdissection. This method ensures tumor purity and unbiased transcriptome profiling while addressing critical challenges like intratumoral heterogeneity. In a study of 1,082 breast tissue samples, mFISHseq demonstrated 93% accuracy compared to IHC and identified biomarkers predictive of responses to targeted therapies, including antibody-drug conjugates and immunotherapies.
We are honored to contribute a tool that holds immense potential for improving outcomes for breast cancer patients globally. This achievment results from the dedication and collaboration of a multidisciplinary team of scientists and clinicians. By combining expertise in genomics, cancer biology, and spatial analytics, they have paved the way for a transformative tool that holds the potential to improve outcomes for breast cancer patients worldwide. We extend our deepest gratitude to the authors for their groundbreaking contributions. Your vision and innovation are shaping the future of oncology and precision medicine.
For more information on our work, please read the full manuscript here: The Spatially Informed mFISHseq Assay Resolves Biomarker Discordance and Predicts Treatment Response in Breast Cancer.
MultiplexDX is one of the most innovative biotech corporations, created to bring its revolutionary technologies to the market of personalized molecular diagnostics. The company has representation in both U.S. and European markets. The collaborators of MultiplexDX are from the world’s most prestigious scientific organizations including the National Cancer Institute, Rockefeller University, Albert Einstein University, Vanderbilt University, Cornell University, Queens University (Canada), Hebrew University of Jerusalem (Israel), and the Max Delbrück Center for Molecular Medicine (Germany).
MultiplexDX IP-based and innovative platform merges histopathology methods, biomarker quantification, visualization and gene expression with a single-cell resolution by combining MDX proprietary visual and sequencing technologies into one diagnostic test. This cross-validation approach eliminates diagnostic errors and creates 100% precise cancer profiling for each patient which allows clinicians to suggest specific, personalized cancer treatment.
Find out more about MultiplexDX on Corporate website, Facebook, LinkedIn, Twitter